Home » Stocks » ORIC

Oric Pharmaceuticals Inc. (ORIC)

Stock Price: $36.09 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $35.37 -0.72 (-2.00%) Jan 15, 6:50 PM
Market Cap 1.28B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 30.31M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $36.09
Previous Close $36.09
Change ($) 0.00
Change (%) 0.00%
Day's Open 33.50
Day's Range 32.47 - 36.38
Day's Volume 1,087,343
52-Week Range 19.50 - 39.80


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021

GlobeNewsWire - 2 weeks ago

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...

GlobeNewsWire - 4 weeks ago

Initiated Part II expansion of the Phase 1b study of ORIC-101 in combination with Abraxane (nab-paclitaxel) using recommended Phase 2 dose selected from Part I of the study

Zacks Investment Research - 1 month ago

ORIC Pharmaceuticals (ORIC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

About ORIC

ORIC Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also develo... [Read more...]

IPO Date
Apr 24, 2020
Jacob Chacko
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ORIC stock is "Strong Buy." The 12-month stock price forecast is 44.14, which is an increase of 22.31% from the latest price.

Price Target
(22.31% upside)
Analyst Consensus: Strong Buy